Per­mi­ra pro­pos­es to take Cam­brex pri­vate in $2.4B deal, stir­ring up CD­MO M&A

Cam­brex is at the M&A game again, but this time it’s switch­ing roles. Af­ter buy­ing out Ha­lo Phar­ma and Avista Phar­ma So­lu­tions in the past cou­ple of years, the con­tract de­vel­op­er and man­u­fac­tur­er is get­ting ac­quired.

Pri­vate eq­ui­ty firm Per­mi­ra Funds has put a $2.4 bil­lion of­fer on the ta­ble for the NYSE-list­ed com­pa­ny, which trans­lates to $60 per share for Cam­brex $CBM stock­hold­ers or a 47.1% pre­mi­um to the clos­ing price the day be­fore. Its stock has surged on rough­ly the same scale.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER